SHANTERA CLARK: Open Payments
NPI 1962020057 · STATESBORO, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,986 in 104 payments from 16 companies in 2025. Trend: 2023 $706 · 2024 $1,458 · 2025 $1,986
Food & beverage: $1,986
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 13 | $287 |
| Neurocrine BioSciences, Inc. | 14 | $285 |
| Alkermes, Inc. | 15 | $217 |
| ABBVIE INC. | 16 | $215 |
| Vanda Pharmaceuticals Inc. | 9 | $211 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $183 |
| Tris Pharma Inc | 6 | $122 |
| Janssen Pharmaceuticals, Inc | 4 | $82 |
| Supernus Pharmaceuticals, Inc. | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
Products named: Auvelity, INGREZZA, ARISTADA, VRAYLAR, FANAPT, CAPLYTA, Dyanavel XR, SPRAVATO.
Industry payments across GA — which companies pay providers there.
